source
- After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationAfter signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.